ЛИГАНДЫ МЕЛАНОКОРТИНОВЫХ РЕЦЕПТОРОВ, МОДИФИЦИРОВАННЫЕ ГИДАНТОИНОМ

Настоящее изобретение относится к пептидным лигандам меланокортиновых рецепторов, в частности рецептора меланокортина-4, и предназначены для лечения заболеваний, реагирующих на активацию данного рецептора, например ожирения, сахарного диабета и половой дисфункции. 10 н. и 3 з.п. ф-лы, 7 ил., 7 табл., 5 пр.

ЛИГАНДЫ МЕЛАНОКОРТИНОВЫХ РЕЦЕПТОРОВ

Изобретение относится к новым циклическим пептидам общей формулы 1 где В - мостиковая группа; Е=Н, галоген, -NO2, -NR8R8' или OR13, R8 и R8' каждый независимо представляет водород или метил; R13 представляет водород или метил; Х - заместители на фенильном кольце, выбранные из водорода, галогена, -NО2 или -OR8; Z - один или более заместителей на фенильном кольце, выбранных независимо из водорода, галогена, -OR9 или две группы Z могут быть взяты вместе с образованием сконденсированного арильного кольца; R9 - водород или метил; D - замещенный или незамещенный имидазолил; R2, R3, R4 и R5 каждый представляет собой водород, метил, или любые два радикала из R2, R3, R4 и R5 могут соединяться с образованием гетероциклического или гетероарильного кольца; р = 1 - 3; и к фармацевтической композиции, обладающей селективностью в отношении рецепторов МС-3 и/или МС-4 по сравнению с другими меланокартиновыми рецепторами. 4 с. и 9 з.п. ф-лы.

VERFAHREN ZUR STIMULIERUNG VON MELANOZYTEN DURCH LOKALES ANBRINGEN VON ALPHA-MSH-ANALOGEN, SOWIE ZUSAMMENSETZUNGEN.

ACTH-Fragmente enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Schockzuständen sowie von respiratorischen und Herz-Kreislauf-Insuffizienzen.

Entzündungshemmende Zusammensetzung

ZYKLISCHE PEPTIDE ALS AGONISTEN FÜR DEN MELANOCORTIN-4-REZEPTOR

Use of antagonists of morphine in the preparation of drugs for purpose immunomodulator and antiviral, in particular intended to treat the acquired immuno-overdrawn states.

Treatment of HIV

Treatment of HIV

Treatment of HIV

Treatment of HIV

MELANOCORTIN RECEPTOR BINDING MIMETIBODIES, COMPOSITIONS, PROCEDURES AND USES

PROCEDURE FOR THE TREATMENT OF ILLNESSES ASSOCIATES INFLAMMATION WITH ACUTES UNDER NICHTISCHÄMI CONDITIONS

USE FROM MORPHINE ANTAGONISTS TO THE PRODUCTION OF MEDICINES WITH IMMUNMODULATORI AND ANTIVIRAL EFFECT, IN PARTICULAR INTENDS FOR THE TREATMENT OF ACQUIRED CONDITIONS OF LACK OF IMMUNE.

ACTIVATION OF REGULATORI T CELLS BY A ALPHA MELANOCYTEN STIMULATING HORMONE

ENTZÜNDUNGSHEMMENDE COMPOSITION

PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR

Short tri- and tetrapeptides according to the following Formula I Ar(CH2).X X2-CO-X 3-X 4-X5-(Trp)n-NX 6R are potent, selective agonists of melanocortin 1 receptor (MC1R). Provided herein are pharmaceutical compositions including 5 Formula I peptide agonists of MC1 R and methods of treating skin diseases and disorders that include administering to an individual in need thereof a therapeutic amount of a Formula I peptide. The peptides, pharmaceutical compositions, and methods described herein are useful in the treatment of diseases and disorders that benefit from agonism of MC1 R, including melanoma, basal cell carcinoma, squamous 10 cell carcinoma, porphyria, polymorphous light eruption, vitiligo, and solar urticaria.

Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof

C-terminal KPV dimers and methods of use

Intranasal administration of active agents to the central nervous system

Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/ AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.

UTILIZATION OF MORPHINE ANTAGONISTS IN THE PREPARATION OF DRUGS HAVING AN IMMUNOMODULATOR AND ANTIVIRAL EFFECT, PARTICULARLY FOR TREATING ACQUIRED IMMUNODEFICIENCY STATES

Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone

A METHOD OF INDUCING MELANOGENESIS IN HUMANS WITH MC1R VARIANT ALLELES

A method for inducing melanogenesis in a human subject having a melanocortin 1 receptor (MC1R) variant allele associated with loss of or diminished receptor function comprises administering to said subject an amount of an .alpha.- melanocyte stimulating hormone (.alpha.-MSH) analogue effective to induce melanogenesis by the melanocytes in the skin or other epidermal tissue of the subject.

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

The present invention is directed to the use of the peptide compound Ac-Ser-Tyr-Ser- Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp- Gly-Lys-Pro-Val-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

ADDITIVE CYTOPROTECTIVE EFFECTS OF TWO BIOACTIVE REGIONS OF PRO-OPIOMELANOCORTIN HORMONE

... ²²²²Bioreactive regions (alpha-melanocte stimulating hormone and met-enkephalin) ²of proopiliomelanocortin ²were identified using computational analysis. Cytoprotection model of the ²ethanol induced gastric lesion was used to prove the additive cytoprotective ²effects of the ²combination of peptide sequences for alpha-melanocte stimulating hormone and ²met-enkephalin. ²These regions KOMET, KOMET-1, KOMET-2 and KOMET-3 exhibit cytoprotective ²effects ²and may be administered to a patient to obtain better and stronger ²pharmacologic effects on the ²systemic and local modulation of inflammation and wound healing.² ...

METHOD OF STIMULATION OF MELANIN PRODUCTION AND INDUCTION OF SKIN TANNING

A method of stimulating the production of melanin by the pigment-producing cells (keratinocytes and/or melanocytes) of the skin, in particular for the induction of skin tanning in humans, comprises administering alpha-MSH or an alpha-MSH analogue and exposing the skin to ultraviolet irradiation.

METHODS FOR TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION UNDER NON-ISCHEMIC CONDITIONS

The present invention relates to a method for treatment or prevention of a non- ischemic condition in one or more organs, the method comprising administering an effective dosage of .alpha.-MSH and/or an .alpha.-MSH equivalent and/or EPO and/or an EPO equivalent to a person in need thereof. In particular, the invention relates to the treatment of inflammation under non-ischemic conditions. Non-limiting examples of such conditions are: Asthma, arthritis, psoriasis, infections, systemic lupus erythematosus, Systemic Sclerosis, allergic rhinitis, allergic and non-allergic conjunctivitis. Moreover, inflammatory diseases also include allergic and non-allergic dermatitis.

IMPLANTABLE PUMP FOR PROTEIN DELIVERY FOR OBESITY CONTROL BY DRUG INFUSION INTO THE BRAIN

An implantable drug infusion pump and a stable suspension of an appetite suppressing agent for use in reducing, ameliorating or preventing obesity is provided. The agent can bind to a target receptor on a neural cell in the central nervous system and upon binding modifies the receptor function to suppress appetite. The agent is an .alpha.-MSH mimetibody polypeptide which has the generic formula: (V1 -Mp-Lk-V2-Hg-C H2-C H3)(t) wherein V1 is an optional amino terminal portion of an immunoglobulin variable region, Mp is an .alpha.-MSH peptide, Lk is a polypeptide or chemical linkage, V2 is a portion of a C-terminus of an immunoglobulin variable region, Hg is at least a portion of an immunoglobulin variable hinge region, C H2 is an immunoglobulin heavy chain C H2 constant region and C H3 is an immunoglobulin heavy chain C H3 constant region and t is independently an integer of 1 to 10.

ENHANCED MELANOMA CANCER PREVENTION BY NOVEL MELANOTROPINS

A gamma-melanocyte stimulating hormone (?-MSH) derivative having improved stability, selectivity and bioavailabilty. The ?-MSH derivative is selective for the melanocortin-1 receptor (MC1 R) and is deliverable to skin cells via topical or transdermal delivery. The ?-MSH derivative is made up of naturally occurring amino acids for stimulating melanin from within for photo- protection of human skin against ultraviolet radiation damage.

MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY

The present invention finds application in the therapeutic fields. In particular, it concerns new synthetic melanocortin peptides having improved antimicrobial activity.

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF DEGENERATIVE DISORDERS IN THE RETINA

Eye diseases or disorders are treated by an active agent being a melanotropin peptide or an analogue thereof, the analogue being an agent having a biological effect resembling that of the melanotropin peptide. The active agent may be administered topically onto the eye, by injection into the eye or systemically.

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR CANCER TREATMENT

ЛЕЧЕНИЕ ВИЧ

Предлагаются способы лечения ВИЧ с помощью пептидов проопиомеланокортина (РОМС) и кортикотропинвысвобождающего фактора (CRF) и их продуктов, а также применение таких пептидов для получения лекарственных средств.

ИНГИБИТОРЫ КАСПАЗ В КАЧЕСТВЕ МАТЕРИАЛА ДЛЯ ПОКРЫТИЯ МЕДИЦИНСКИХ ПРОДУКТОВ ДЛЯ ИНГИБИРОВАНИЯ РЕСТЕНОЗА

Настоящее изобретение относится к фармацевтической композиции, содержащей ингибитор каспаз и/или соединение общей формулы R-Lys-X, способам нанесения покрытия на медицинские продукты с использованием указанных ингибиторов каспаз и/или указанных соединений общей формулы R-Lys-X и к медицинским продуктам с покрытием из указанных ингибиторов каспаз и/или указанных соединений общей формулы R-Lys-X, где данное покрытие ингибирует рестеноз.

ИНГИБИТОРЫ КАСПАЗ В КАЧЕСТВЕ МАТЕРИАЛА ДЛЯ ПОКРЫТИЯ МЕДИЦИНСКИХ ПРОДУКТОВ ДЛЯ ИНГИБИРОВАНИЯ РЕСТЕНОЗА

Настоящее изобретение относится к фармацевтической композиции, содержащей ингибитор каспаз и/или соединение общей формулы R-Lys-X, способам нанесения покрытия на медицинские продукты с использованием указанных ингибиторов каспаз и/или указанных соединений общей формулы R-Lys-X и к медицинским продуктам с покрытием из указанных ингибиторов каспаз и/или указанных соединений общей формулы R-Lys-X, где данное покрытие ингибирует рестеноз.

SUPPRESSION OF ITCH

PEPTIDES FOR USE IN THE TREATMENT OF OBESITY

The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

PEPTIDES FOR TREATMENT OF OBESITY

The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

FUSION PROTEIN FOR Á MELANOCYTE STIMULATING HORMONE AND PREPARATION METHOD AND USE THEREOF

Disclosed is a fusion protein for á melanocyte stimulating hormone, the fusion protein containing a protein transduction domain (PTD), a human serum albumin (HSA) and an á-melanocyte stimulating hormone (á-MSH). Also disclosed are a method for preparing the fusion protein and a use thereof for inhibiting or treating central nervous system inflammations.

TRIMERIC PEPTIDES FOR USE IN TREATING OBESITY

The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

A URO-GENITAL CONDITION TREATMENT SYSTEM

Système pour le traitement d'une pathologie urogénitale. Selon un aspect de la présente invention, ledit système de traitement comporte un ou plusieurs polypeptides dont la séquence d'acides aminés comprend KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), pour le traitement de pathologies urogénitales. Lesdits polypeptides peuvent également être un dimère formé à partir de l'une des séquences d'acides aminés susmentionnées. Les pathologies urogénitales concernées peuvent être une infection, une inflammation, ou les deux. Dans un mode de réalisation préféré de la présente invention, la pathologie urogénitale est une infection et/ou inflammation du vagin, de la vulve, des voies urinaires, du pénis, et/ou du rectum. Dans un autre mode de réalisation préféré, lesdits polypeptides sont dissous dans un excipient. Dans un autre mode de réalisation préféré encore, lesdits polypeptides sont associés à un tampon pour éviter le syndrome de ...

MELANOCORTIN RECEPTOR LIGANDS

Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R2, R4, R4', R5, R6, R6', R7, R8, R8', R9, R9', R10, Ar, Z1, Z2, Z3, X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.

COMPOSITION COMPRISING A MELANOCORTIN RECEPTOR (MCR) MODULATING AGENT ALONE OR IN COMBINATION WITH A SECOND NEUROGENIC AGENT FOR TREATING NERVOUS SYSTEM DISORDERS

The present disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a melanocortin receptor (MCR) modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Use of KPV tripeptide for dermatological disorders

The present invention is directed to a prevention and treatment for dermatological disorders. One aspect of this invention involves a dermatological treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment and prevention of dermatological disorders. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above.

Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders

A system comprising a combination of at least one MCI R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.

CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY

Anti-inflammatory composition

ЛИГАНДЫ МЕЛАНОКОРТИНОВЫХ РЕЦЕПТОРОВ

... 1. Циклический пептидный аналог, имеющий формулу (I): в которой (В) представляет мостиковую группу, выбранную из: или Е представляет водород, галоген, -NO2, -NR8 R8' или -OR13; R8 и R8' каждый независимо представляет водород или метил; R13представляет водород или метил; Х представляет заместители на фенильном кольце, где каждый из заместителей выбран независимо из водорода, галогена, -NO2 или -OR8; каждый R8 представляет водород или метил; Z представляет один или более заместителей на фенильном кольце, выбранных независимо из водорода, галогена, -OR9, или две группы Z могут быть взяты вместе с образованием сконденсированного арильного кольца; R9 представляет водород или метил; D выбран из i) ii) замещенный или незамещенный имидазолил; iii) R2, R3, R4 и R5 каждый представляют водород, метил, или любые два радикала из R2, R3, R4 и R5 могут соединяться с образованием гетероциклоалкильного или гетероарильного кольца; и р равно от 1 до 3. 2. Соединение по п.1, имеющее следующую стереохимическую ...

СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH

... 1. Способ синтеза Ac-Arg-цикло(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHв жидкой фазе, включающий методику конденсации фрагментов.2. Способ синтеза Ac-Arg-цикло(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHв жидкой фазе по п.1, в котором используют защищенные аминокислоты.3. Способ синтеза Ac-Arg-цикло(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHв жидкой фазе по п.2, в котором указанные защищенные аминокислоты выбраны из группы, состоящей из аминокислот, защищенных Boc, аминокислот, защищенных бензилоксикарбонилом, аминокислот, защищенных Fmoc и защищенных фторангидридов аминокислот.4. Способ синтеза Ac-Arg-цикло(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHв жидкой фазе по п.3, где указанный защищенный фторангидрид аминокислоты представляет собой фторангидрид Fmoc аминокислоты или фторангидрид Bsmoc аминокислоты.5. Способ синтеза Ac-Arg-цикло(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHв жидкой фазе по любому из пп.1-4, где применяется методика сшивания смешанного ангидрида.6. Способ синтеза Ac-Arg-цикло(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys ...

АДДИТИВНЫЕ ЦИТОПРОТЕКТОРНЫЕ ЭФФЕКТЫ ДВУХ БИОАКТИВНЫХ ОБЛАСТЕЙ ГОРМОНА ПРО-ОПИОМЕЛАНОКОРТИНА

... 1. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET, характеризующихся структурными формулами SYSMEHFRWGKPV и YGGFM (таблица 1), для синтеза лекарств, которые используются как системные и местные препараты. 2. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET-1, характеризующихся структурной формулой YGGFMSYSMEHFRWGKPVYGGFM, для синтеза лекарств, которые используются как системные и местные препараты. 3. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET-2, характеризующихся структурными формулами YGGFMSYSMEHFRWGKPV, для синтеза лекарств, которые используются как системные и местные препараты. 4. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET-3, характеризующихся структурными формулами SYSMEHFRWGKPVYGGFM, для синтеза лекарств, которые используются как системные и местные препараты.

ПРИМЕНЕНИЕ ПЕПТИДА В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА

... 1. Применение пептида Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 или его солей, гидратов или деацетилированной формы для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где инфекционное заболевание представляет собой бактериальное, грибковое или вирусное инфекционное заболевание, которое выбрано из альвеолярного гидатидного заболевания (AHD, эхинококкоза), амебиаза (инфекции Entamoeba histolyca), инвазии Angiostrongylus, анизакиаза, сибирской язвы, бабезиоза (инфекции Babesia), инфекции Balantidum (балантидиаз), инфекции Blastocystis hominis (бластомикоза), боррелиоза, ботулизма, диареи Брайнерда, бруцеллеза, капилляриоза (инвазии Capillaria), синдрома хронической усталости (CFS), болезни Шагаса (американский ...

MELANOCORTINREZEPTOR LIGAND

Therapeutically active alpha-MSH analogues

Oligopeptides as coating material for medical products

Frequency assisted transdermal agent delivery method and system

Use of kpv tripeptide for dermatological disorders

Use of a peptide as a therapeutic agent

INTRANASAL ADMINISTRATION OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM

A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering the fusion polypeptide intranasally, for delivery to the central nervous system. Methods of treatment are also provided, where a therapeutically effective amount of the composition is delivered to the nasal cavity of a mammal.

PEPTIDE ANALOGS OF ALPHA-MELANOCYTE STIMULATING HORMONE

Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (.alpha.-MSH) having selectivity for the melanocortin 1 receptor (MClR). Also provided herein are pharmaceutical preparations of the .alpha.-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MClR.

OLIGOPEPTIDES AS COATING MATERIAL FOR MEDICAL PRODUCTS

TRIPEPTIDE KDPT FOR ANTIAPOPTOTIC TREATMENT

The present invention is related to the tripeptide (l)Lys-(d)Pro-(l)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti- apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis.

ЛЕЧЕНИЕ ВИЧ

Описываются способы лечения ВИЧ с помощью пептидов проопиомеланокортина (РОМС) и кортикотропинвысвобождающего фактора (CRF) и их продуктов, а также применение таких пептидов для получения лекарственных средств.

СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ЛИМФОМОЙ ХОДЖКИНА ГРУППЫ ВЫСОКОГО РИСКА

Способ лечения больных лимфомой Ходжкина группы высокого риска предусматривает проведение курсов полихимиотерапии больным с II В, III-IV стадиями. Каждый последующий курс лечения начинают через 14 дней в сниженных дозах цитостатических препаратов.

Peptide analogs of alpha-melanocyte stimulating hormone

Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (alpha-MSH) having selectivity for the melanocortin 1 receptor (MClR). Also provided herein are pharmaceutical preparations of the alpha-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MClR.

NEW THERAPEUTIC APPLICATION Of the 17 (CYCLOPROPYLMETHYL) - 4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND the INTENDED PHARMACEUTICAL COMPOSITIONS HAS THIS USE

METHOD OF TREATING BOWEL HYPERPERMEABILITY, METHOD FOR TREATING DIABETES, METHOD OF TREATING AUTISM, METHOD FOR TREATING FIBROMYALGIA, METHOD OF TREATING AT LEAST ONE DISEASE, PHARMACEUTICAL COMPOSITION, KIT AND METHOD TREATING HYPERGLYCEMIA

NEW INDICATION FOR ALPHA-MSH ANALOGUES

The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders.

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

The present invention is directed to the use of the peptide compound Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC FATIGUE SYNDROME AND NEURODEGENERATIVE DISEASES

The present invention relates to use of pharmaceutical formulations of α-MSH for the treatment of chronic fatigue syndrome and neurodegenerative diseases.

A URO-GENITAL CONDITION TREATMENT SYSTEM

Système pour le traitement d'une pathologie urogénitale. Selon un aspect de la présente invention, ledit système de traitement comporte un ou plusieurs polypeptides dont la séquence d'acides aminés comprend KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), pour le traitement de pathologies urogénitales. Lesdits polypeptides peuvent également être un dimère formé à partir de l'une des séquences d'acides aminés susmentionnées. Les pathologies urogénitales concernées peuvent être une infection, une inflammation, ou les deux. Dans un mode de réalisation préféré de la présente invention, la pathologie urogénitale est une infection et/ou inflammation du vagin, de la vulve, des voies urinaires, du pénis, et/ou du rectum. Dans un autre mode de réalisation préféré, lesdits polypeptides sont dissous dans un excipient. Dans un autre mode de réalisation préféré encore, lesdits polypeptides sont associés à un tampon pour éviter le syndrome de ...

PEPTIDES FOR USE IN THE TREATING OBESITY

The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

ENZYME INHIBITORS

A compound of Formula (I) wherein R is a biomolecular residue, or derivative thereof, of a C-terminal amide biomolecule which is activated by the action of PAM; and X is O or CH2 or a salt, or prodrug thereof.

Method for teeth whitening

Verfahren zum Aufhellen von Zähnen bei dem man (a) ein Bleichmittel auf die Oberfläche des oder der zu bleichenden Zähne aufträgt, (b) man das Bleichmittel für einen Zeitraum von 3 bis 30 Minuten auf den Zahn einwirken läßt, (c) man das Bleichmittel von der Zahnoberfläche entfernt, (d) man die Schritte (a) bis (c) mindestens einmal wiederholt und Kit zur Durchführung des Verfahrens.

MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY

Entzündungshemmende Zusammensetzung

Non-inflammatory stimulators of type 2 or type 3 beta-defensins

Active ingredients capable of stimulating directly or indirectly the expression of type 2 or type 3 beta defensins in humans, but which do not stimulate either inflammatory, irritation or intolerance reactions, or the synthesis of proinflammatory molecules, such as MIP 3 alpha, IL8, IL1 or other interleukins, histamine, tryptase, substance P or leucotrines or prostaglandins. More preferably the active ingredient is chosen from a plant or extract thereof, such as artemisia, erigeron, elderberry, rupturewort, pineapple, peppermint, areca, cocoa, quinoa, arnica, boldo, sarsparilla, walnut, hibiscus, pumpkin, sunflower, peony, St John's wort, horse chestnut, or from jasmonic acid, vitamin A, alpha-MSH, isoluencine esters or organic or mineral calcium. Also claimed are assay and methods for screening for such compounds, as well as cosmetic and pharmaceutical compounds containing such active ingredients.

USE OF ALPHA MSH AND EPO FOR THE PRODUCTION OF A DRUG FOR THE PROPHYLAXIS OR TREATMENT OF THROUGH ISCHEMIC CONDITIONS CAUSED DISEASES

PROCEDURE FOR THE STIMULATION OF MELANOZYTEN BY LOCAL ATTACHMENT OF ALPHA MSH SIMILAR ONES, AS WELL AS COMPOSITIONS.

CUTANEOUS METABOLIC BIO-ACTIVATOR

Use of alpha-MSH and EPO for preventing or treating ischemic conditions

Method of stimulation of melanin production and induction of skin tanning

METHODS FOR TREATING PAIN

Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions.

COMPOSITIONS FOR STIMULATING INTERGUMENTAL MELANOCYTES BY TOPICAL APPLICATION OF ANALOGS OF ALPHA-MSH AND COMPOSITIONS FOR USE IN SAME

The present invention relates to topically administered pharmaceutical compositions of certain alpha-MSH analogs useful in the stimulation of integumental melanocytes for melanin production in vertebrates.

PHARMACEUTICAL COMPOSITIONS AND METHODS

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.

MELANOCYTE STIMULATING HORMONE AS DERMATITIS TREATMENT

... \ USE OF MELANOCYTE STIMULATING HORMONE AS DERMATITIS TREATMENT Dermatitis is treated by topically applying a composition including melanocyte stimulating hormone to the epidermal portion of the infected skin. Preferably, alpha-melanocyte stimulating hormone is applied in a concentration in the range of about 5 x 10-5 M/cm2. This is an effective treatment against a broad range of dermatitis. Occlusion of the affected site enhances response.

Treatment of HIV

本发明描述了利用阿黑皮素原(POMC)和促肾上腺皮质激素释放因子(CRF)肽及其产物治疗HIV的方法，以及所述肽在制备药物中的用途。

COMBINE TRIPEPTIDIQUES AGONISTES OF THE MSH

NOUVELLE APPLICATION THERAPEUTIQUE DE LA 17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE ET LES COMPOSITIONS PHARMACEUTIQUES DESTINEES A CET USAGE

L'INVENTION SE RAPPORTE AU DOMAINE DE L'INDUSTRIE PHARMACEUTIQUE ET PLUS PARTICULIEREMENT A UN MEDICAMENT, UTILE DANS LE TRAITEMENT DES ETATS IMMUNO-DEFICITAIRES ACQUIS, NOTAMMENT LE SIDA. ELLE A PLUS PARTICULIEREMENT POUR OBJET UNE NOUVELLE APPLICATION THERAPEUTIQUE DE LA 17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE (ET DE SES DERIVES EVENTUELS) OU DE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES SOUS LA FORME DE COMPOSITIONS PHARMACEUTIQUES RENFERMANT AU MOINS 50 MILLIGRAMMES DE PRINCIPE ACTIF PAR DOSE UNITAIRE, ASSOCIE A AU MOINS 75 MILLIGRAMMES DE LACTOSE EN ADDITION AVEC AU MOINS 45 MILLIGRAMMES D'ACETATE DE ZINC. LE COMPOSE EN QUESTION A LA DOSE JOURNALIERE DE 50 A 800 MILLIGRAMMES EST UTILE EN TANT QU'AGENT IMMUNOMODULATEUR.

Cosmetic or dermatological skin-treatment composition, useful e.g. for sun-tanning, comprises a complex of an endonuclease with a nucleotide or nucleic acid

Composition cosmétique et/ou dermocosmétique, caractérisée en ce qu'elle comprend un complexe actif constitué d'au moins un peptide ou une protéine choisi dans le groupe constitué par les endonucléases, le peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser, l'alpha MSH ("melanocyte stimulating hormon"), la mélanostatine, et la photolyase, et d'au moins un nucléotide, polynucléotide, ou acide nucléique choisi dans le groupe constitué par l'AMP, GMP, CMP, UMP, dTMP, dAMP, dCMP, dGMP, ATP, GTP, CTP, UTP, TMP, GP4G, IP3, les hydrolysats d'ADN, et/ou ARN, l'UDP-glucose-galactose, le GDP-mannose, l'UDP-N-acétyl glusosamine, le CMP-N-acétyl acide neuramique.

A URO-GENITAL CONDITION TREATMENT SYSTEM

The present invention is directed to a system for treating uro-genital conditions. One aspect of this invention involves the treatment system comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), for treatment of uro-genital conditions. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above. Uro- genital conditions can include infections, inflammation, or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and/or inflammation of the vagina, vulva, urinary tract, penis, and/or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one ...

[...] that bind to melanocortin receptor, compositions, methods and uses

THERAPEUTICALLY ACTIVE ALPHA-MSH ANALOGUES

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

The present invention is directed to the use of the peptide compound Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-lle-Leu-Thr-Met-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

UTILIZATION OF MORPHINE ANTAGONISTS IN THE PREPARATION OF DRUGS HAVING AN IMMUNOMODULATOR AND ANTIVIRAL EFFECT, PARTICULARLY FOR TREATING ACQUIRED IMMUNODEFICIENCY STATES

Utilization of morphine antagonists, such as Naltrexone, beta-endorphine 1-27, or their derivatives or analogs, in the preparation of an immunomodulator and/or antiviral drug for the treatment of acquired immunodeficiency states, particularly the infection by HIV.

POSITIVE ALLOSTERIC MODULATORS OF HUMAN MELANOCORTIN-4 RECEPTOR

Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.

Peptide analogs of alpha-melanocyte stimulating hormons

Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (α-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the α-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.

ПЕПТИДНЫЕ АНАЛОГИ АЛЬФА-МЕЛАНОЦИТСТИМУЛИРУЮЩЕГО ГОРМОНА

Изобретение относится к стабильным пептидным аналогам альфа-меланоцитстимулирующего гормона (α-MSH), которые имеют сродство к рецептору меланокортина 1 (MC1R), фармацевтическим препаратам пептидных аналогов α-MSH, а также к способам применения этих аналогов для лечения заболеваний в медицине и в ветеринарии, связанных с MC1R. 11 н. и 5 з.п. ф-лы, 22 ил., 2 табл., 23 пр.

Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel

Die Erfindung betrifft eine topisch anwendbare hautkosmetische Zusammensetzung zur Verwendung als Hautbräunungsmittel, die durch einen wirksamen Gehalt an Melanotan II in einem kosmetisch verträglichen Träger gekennzeichnet ist. The invention relates to a topically applicable skin cosmetic composition for use as a skin tanning agent, which is characterized by an effective content of Melanotan II in a cosmetically compatible carrier.

Kosmetische Verwendung eines Wirkstoffs zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3, Verwendung eines solchen Wirkstoffs zur Herstellung einer pharmazeutischen Zusammensetzung, die einen solchen Wirkstoff enthält und Verwendung eines solchen Wirkstoffs auf dem Gebiet der Geweberekonstruktion

Kosmetische Verwendung eines Wirkstoffs, der ausgewählt ist aus der Gruppe bestehend aus einem Boldo-Extrakt, einem Kakao-Extrakt und Jasmonsäure, wobei der Extrakt erhalten wird durch wässrige Extraktion oder Extraktion mit Wasser-Butylenglycol zur Ausübung einer bakteriziden und/oder fungiziden Wirkung auf behandeltes Gewebe, durch direkte oder indirekte Stimulierung der Expression von humanen beta-Defensinen vom Typ 2 (hBD2) und/oder vom Typ 3 (hBD3), ohne ein proinflammatorisches Molekül zu stimulieren, das im Verlauf von Entzündungsprozessen co-exprimiert wird, ausgewählt aus der Gruppe bestehend aus MIP 3 alpha (Makrophageninflammationsprotein), IL8 und IL1.

FORMULATION

The present invention relates to a CRH formulation having improved stability/efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation. 2. The method of claim 1 , wherein the serum is frozen after step (d) and thawed prior to patient administration with the proviso that said serum is not subjected to a subsequent freezing step prior to said patient administration.3. The method of claim 1 , wherein the nanofiltration step is carried out using a 35 nanometre filter claim 1 , for example using a 35 nanometre hollow fibre filter.4. The method of claim 1 , further comprising the step of adjusting the final protein concentration to 4-5 milligrams protein per millilitre.5. The method of claim 4 , wherein the hyperimmune serum is only frozen after said adjusting of the final protein concentration.6. The method of claim 1 , wherein exposure to ambient temperature is strictly minimised at all stages of the method.7. A formulation comprising a stabilised complex of corticotropin releasing hormone (CRH) and alpha-2 macroglobulin claim 1 , wherein the formulation is produced by the method of .8. A formulation comprising a stabilised complex of corticotropin releasing hormone (CRH) and alpha-2 macroglobulin claim 1 , wherein the formulation comprises more than 50 claim 1 ,000 pg/ml of alpha-2 macroglobulin.9. The formulation of claim 8 , comprising between 100 claim 8 ,000 pg/ml and 150 claim 8 ,000 pg/ml of alpha-2 macroglobulin.10. The formulation of claim 8 , wherein the formulation when administered to a patient results in an in vivo CRH expression concentration that is greater after 36 hours than after 48 hours from the time of administration.11. The formulation of claim 8 , comprising 80-120 pg/ml of CRH.12. The formulation of claim 11 , comprising 90-110 pg/ml of CRH.13. The formulation of claim 8 , ...

TREATMENT OF HIV

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation and medicaments. 119.-. (canceled)20. A method of treatment of HIV comprising administering a corticotropin releasing factor (CRF) peptide to a patient.21. The method of claim 20 , wherein one or more of the following effects is achieved: a reduction in viral load; an increase in CD4 cells; or an increase in CD8 cells.22. The method of wherein the CRF is non-human CRF.23. The method of wherein the CRF is goat CRF.24. The method of further comprising administering one or more peptide regulatory or releasing factors.25. The method of wherein the factors are selected from the group comprising α-HLA claim 24 , TGF-β claim 24 , and IL-10.26. The method of further comprising administering one or more of vasopressin claim 20 , β-endorphin claim 20 , and an enkephalin.27. The method of further comprising administering CRF binding protein (CRF-BP).28. The method of further comprising administering a POMC peptide or a POMC product.29. A method of treatment of HIV comprising administering a POMC peptide and/or a POMC product to a patient.30. A method of treatment of HIV comprising administering two or more of alpha claim 20 , beta claim 20 , and gamma melanocyte stimulating hormone (MSH); adrenocorticotrophin (ACTH); beta and gamma lipotropin (LPH); and beta endorphin.31. A method for the treatment of HIV in a patient claim 20 , said method comprising administering to said patient a composition selected from the group consisting of (i) a corticotropin releasing factor (CRF) peptide and a POMC peptide and (ii) a CRF peptide and a POMC product.32. The method of wherein said CRF peptide is a non-human CRF peptide.33. The method of wherein said non-human CRF peptide is a goat CRF peptide.34. The method of wherein said administering achieves an effect selected from the group consisting of: ...

MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell. 1. A modified melanocortin 1 receptor (MC1R) peptide ligand , comprising an MC1R peptide ligand coupled to a functionality.2. The modified MC1R peptide ligand of claim 1 , wherein said functionality is an alkyne claim 1 , azide claim 1 , amine claim 1 , aldehyde claim 1 , thiol claim 1 , alkene claim 1 , ester claim 1 , or maleimide.3. The modified MC1R peptide ligand of claim 1 , wherein said functionality is coupled to the C-terminus of said MC1R ligand.4. The modified MC1R peptide ligand of claim 1 , wherein said functionality is coupled to the N-terminus of said MC1R ligand.6. The modified MC1R peptide ligand of claim 1 , wherein said MC1R peptide ligand comprises the amino acid motif His-Phe-Arg-Trp (HFRW) (SEQ ID NO:1).7. The modified MC1R peptide ligand of claim 1 , wherein said MC1R peptide ligand comprises the amino acid motif His-DPhe-Arg-Trp (HfRW) (SEQ ID NO:2).8. A method selected from among:(a) a method of preparing a MC1R peptide ligand comprising an ...

THERAPY FOR VITILIGO

The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo. 1. Method for treating or preventing vitiligo in a subject comprising administering to the subject a therapeutically or prophylactically effective amount of an alpha-MSH analogue.2. Method according to claim 1 , further comprising the step of exposing the subject to an effective amount of narrow band ultraviolet B (NB-UVB) light.3. Method according to claim 2 , wherein the subject is exposed to NB-UVB light treatment and to alpha-MSH analogue at the same time.4. Method according to claim 2 , wherein the subject is exposed to NB-UVB light treatment during a period of at least 1 week before administration of the alpha-MSH analogue.5. Method according to claim 2 , wherein the subject is exposed to NB-UVB light treatment during a period of at least 1 week after administration of the alpha-MSH analogue.7. Method according to claim 1 , wherein the subject has Fitzpatrick skin type IV claim 1 , V or VI.8. Method according to claim 1 , wherein the alpha-MSH analogue is present in the blood plasma of the subject at a concentration of from 0.001 ng/ml to 10 ng/ml for a period of at least 2 days.9. Method according to claim 1 , wherein the alpha-MSH analogue is systemically administered by subcutaneous claim 1 , intramuscular claim 1 , intraperitoneal or intravenous injection.11. Method according to claim 1 , wherein the alpha-MSH analogue is [Nle claim 1 , D-Phe]-alpha-MSH.12. Method according to claim 1 , wherein the alpha-MSH analogue is administered in a composition further comprising one or more agents selected from the group consisting of ...

COMBINATION OF A MC1R RECEPTOR AGONIST AND UVB FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS

A system comprising a combination of at least one MC1R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation. 1. A system comprising a combination of at least one MC1R receptor agonist and a source of NB-UVB , wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.3. The system according to claim 2 , wherein said MC1R agonist is selected from compounds of formula (II) claim 2 , wherein:R1 is a cyclopropylmethyl group or a 4-hydroxybutyl;R2 represents a hydrogen atom, a methyl group; and respective salts and enantiomers.4. The system according to claim 1 , wherein said MC1R agonist is present in a composition applied topically or administered orally.5. The system according to claim 4 , wherein said composition comprises claim 4 , in a cosmetically acceptable medium claim 4 , at least one MC1R agonist.6. The system according to claim 4 , wherein said MC1R agonist is present in the composition at a concentration between about 0.001% and 10% by weight based on the total weight of the composition comprising it.7. The system according to claim 1 , wherein NB-UVB length wave is selected between 280 nm and 315 nm.8. The system according to claim 1 , wherein the skin disease associated with hypopigmentation is selected from the group consisting of vitiligo claim 1 , albinism claim 1 , hypomelanoses claim 1 , depigmentation by physical or chemical agents claim 1 , post-inflammatory hypopigmentation claim 1 , phenomenon of Sutton and other hypopigmentation lesions.9. A method of treating a dermatological condition linked to a hypopigmentation claim 1 , the method comprising administering to an ...

Topical systems and methods for treating sexual dysfunction

The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Methods of Improving Behavioral Therapies

This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy. 1. A method of improving reciprocal social interactions during a psychotherapy treatment comprising administering an effective amount of a pharmaceutical composition comprising melanotan II or salt thereof to a subject diagnosed with autism , Asperger syndrome , or an autistic spectrum disorder wherein the administration is about the time period a psychotherapy session is being conducted and the session includes exposure to a reciprocal social interaction.2. The method of wherein the administration is administered during the psychotherapy session.3. The method of wherein the administration is within five minutes of a psychotherapy session.4. The method of claim 1 , wherein the administration is within one hours of a psychotherapy session.5. The method of claim 1 , wherein the administration is within five hours of a psychotherapy session. This application is a division of U.S. application Ser. No. 14/017,423 filed Sep. 3, 2013, which is a continuation of U.S. application Ser. No. 13/111,293 filed May 19, 2011, which claims the benefit of priority to U.S. Provisional Application No. 61/346,730 filed May 20, 2010. The entirety of each of these applications is hereby incorporated by reference for all purposes.The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 09167USDIV_ST25.txt. The text file is 11 KB, was created on Oct. 3, 2017, and is being submitted electronically via EFS-Web.This disclosure describes the use of certain compounds that act to ...

PEPTIDE ANALOGS OF ALPHA-MELANOCYTE STIMULATING HORMONE

Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (α-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the α-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R. 1. A substantially pure compound that selectively binds melanocortin 1 receptor (MC1R) , said compound comprising a polypeptide having the sequence:{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13, 'XaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaa,'}{'sub': '1', 'claim-text': [{'sub': '2', 'Xaais D-Pro, D-Ala or D-Lys;'}, {'sub': '3', 'Xaais D-Lys, D-Orn, D-Nle, D-Ala or D-Lys;'}, {'sub': '4', 'Xaais Gly, or D-Ala;'}, {'sub': '5', 'Xaais D-Trp, Trp, D-3-benzothienyl-Ala, D-5-hydroxy-Trp, D-5-methoxy-Trp, D-Phe, or D-Ala;'}, {'sub': '6', 'Xaais D-Arg, D-His, or D-Ala;'}, {'sub': '7', 'Xaais D-Cha, D-Phe, Phe, D-4-fluoro-Phg, D-3-pyridyl-Ala, D-Thi, D-Trp, D-4-nitro-Phe, or D-Ala;'}, {'sub': '8', 'Xaais D-His, His, D-Arg, Phe, or D-Ala;'}, {'sub': '9', 'Xaais D-Glu, D-Asp, D-citrulline, D-Ser, or D-Ala;'}, {'sub': '10', 'Xaais D-Met, D-buthionine, D-Ile, or D-Ala;'}, {'sub': '11', 'Xaais D-Ser, D-Ile or D-Ala;'}, {'sub': '12', 'Xaais D-Tyr, D-Ser, or D-Ala; and'}, {'sub': '13', 'Xaais D-Ser or D-Ala;'}], 'wherein Xaais D-Val, D-Ala or D-Lys;'}{'sub': 1-13', '1-3', '1-13, 'wherein no more than one Xaais D-Ala except when Xaaare all D-Ala, and no more than one Xaais an L-amino acid;'}or a pharmaceutically acceptable salt thereof.2. The compound of claim 1 , said compound comprising a polypeptide having the sequence:{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '1, 'claim-text': [{'sub': '2', 'Xaais D-Pro;'}, {'sub': '3', 'Xaais D-Lys, D-Orn or D-Nle;'}, {'sub': '4', 'Xaais Gly;'}, {'sub': '5', 'Xaais D-Trp, Trp, D-3-benzothienyl-Ala, D-5-hydroxy-Trp, D-5-methoxy-Trp, or D-Phe ...

USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION

Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects. 125-. (canceled)26. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction and anticipating sexual activity , said method comprising administering to the female patient by subcutaneous injection a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide in an amount sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/mL within 60 minutes after administration of the composition.27. The method of claim 26 , wherein the peak plasma concentration of bremelanotide is no more than 100 ng/mL within 60 minutes after administration of the composition.28. The method of claim 26 , wherein the composition comprises 1.75 mg net peptide weight of bremelanotide.29. The method of claim 26 , wherein the composition is an aqueous solution comprising an acetate salt of bremelanotide and glycerin.30. The method of claim 29 , wherein the composition comprises 2.5% glycerin (w/v).31. The method of claim 29 , wherein the acetate salt of bremelanotide is between 6% and 12% acetic acid (w/w) in an aqueous solution of bremelanotide.32. The method of claim 31 , wherein the composition has a pH of about 5.0 claim 31 , and wherein the composition further comprises one or more agents to adjust pH.33. The method of claim 32 , wherein the one or more agents to adjust pH are selected from the group consisting of hydrochloric acid and sodium hydroxide.34. The method of claim 33 , wherein the composition comprises 1.75 mg net peptide weight of bremelanotide.35. The method of claim 26 , wherein the female patient is premenopausal.36. The method of claim 26 , wherein the female patient is postmenopausal.37. The method ...

TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHY

Treatments for synucleinopathy including Parkinson's Disease (PD), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB) are largely unavailable. The invention provides methods for treating, preventing, inhibiting, and reversing synucleinopathy by attenuating MSH activity, decreasing MSH expression, or by modulating MSH engagement with its receptor by utilizing antagonists. Furthermore, the inventor has provided a method for producing a synucleinopathy animal model for screening treatments and for studying synuclein disease pathology.

Memory or learning improvement using peptide and other compositions

The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

ENHANCED MELANOMA CANCER PREVENTION BY NOVEL MELANOTROPINS

A gamma-melanocyte stimulating hormone (γ-MSH) derivative having improved stability, selectivity and bioavailabilty. The γ-MSH derivative is selective for the melanocortin-1 receptor (MC1 R) and is deliverable to skin cells via topical or transdermal delivery. The γ-MSH derivative is made up of naturally occurring amino acids for stimulating melanin from within for photoprotection of human skin against ultraviolet radiation damage. 2. The MC1R peptide ligand according to claim 1 , wherein Waa is Leu claim 1 , Xaa is His claim 1 , Yaa is Leu claim 1 , Zaa is Phe claim 1 , and R1 is —NH.4. (canceled)5. The MC1R peptide ligand of claim 1 , wherein the MC1R peptide ligand is selective for MC1R claim 1 , wherein the MC1R peptide ligand is an agonist of MC1R.6. The MC1R peptide ligand of claim 1 , wherein the MC1R peptide ligand is at least twice as selective for MC1R than MC3R claim 1 , MC4R claim 1 , or MC5R.7. (canceled)8. The MC1R peptide ligand of claim 1 , wherein the MC1R peptide ligand is capable of stimulating melanin production.11. (canceled)12. The pharmaceutical composition of claim 9 , wherein the MC1R peptide ligand is present in an amount ranging from about 0.001-20 wt % of the pharmaceutical composition.13. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is administered topically for delivering the MC peptide ligand through skin.14. The pharmaceutical composition according to claim 13 , wherein the pharmaceutical composition is in a form selected from a group consisting of a gel claim 13 , a hydrogel claim 13 , a water-in-oil emulsion claim 13 , an oil-in-water emulsion claim 13 , a cream claim 13 , a lotion claim 13 , an ointment claim 13 , a spray claim 13 , a foam claim 13 , a multi-emulsion claim 13 , and a liposome.15. The pharmaceutical composition according to claim 13 , wherein the pharmaceutical composition is in a form of a patch claim 13 , said patch comprising an impenetrable outer layer claim 13 , and a ...

Brain and neural treatments comprising peptides and other compositions

The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

NDP-MSH FOR TREATMENT OF INFLAMMATORY AND/OR NEURODEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM

The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof. 1. A method of treatment of inflammatory and/or neurodegenerative disorders of the Central Nervous System (CNS) in a subject in need thereof comprising administering NDP-MSH or pharmaceutically acceptable salts thereof.2. The method of claim 1 , wherein the inflammatory and/or neurodegenerative disorder of the CNS is multiple sclerosis.3. The method of claim 1 , wherein the treatment comprises therapeutic and/or a therapeutic prophylactic treatment.4. The method of claim 1 , wherein the treatment has an anti-inflammatory and/or neuroprotective effect.5. The method of claim 1 , wherein the subject is a mammal.6. The method of claim 1 , wherein NDP-MSH or a pharmaceutically acceptable salt thereof is chemically modified.7. The method of claim 1 , wherein NDP-MSH is administered during relapse claim 1 , progression and/or remission.8. The method of claim 1 , wherein NDP-MSH or a pharmaceutically acceptable salt thereof is administered intravenously.9. The method of claim 1 , wherein 1-500 μg/kg of body weight of NDP-MSH or the pharmaceutically acceptable salt is administered.10. The method of claim 1 , wherein NDP-MSH is administered in repeatedly in intervals of 12-72 hours.11. A pharmaceutical composition comprising NDP-MSH or pharmaceutically acceptable salts thereof in an amount effective for the treatment of inflammatory and/or neurodegenerative disorders of the CNS.12. The pharmaceutical composition of claim 11 , wherein the inflammatory and/or neurodegenerative disorder of the CNS is multiple sclerosis.13. A kit for use in the treatment of inflammatory and/or neurodegenerative disorders of ...

Oral Administration of Tocilizumab Treatment of Autoimmune Disease

The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of tocilizumab. 1. A method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject an effective dose of tocilizumab.2. The method of claim 1 , wherein the tocilizumab is administered in a liquid form.3. The method of claim 1 , wherein the tocilizumab is administered in a solid form.4. The method of claim 1 , wherein the condition is rheumatoid arthritis claim 1 , psoriasis claim 1 , type 1 diabetes claim 1 , systemic lupus erythematosus claim 1 , transplant rejection claim 1 , autoimmune thyroid disease (Hashimoto's disease) claim 1 , sarcoidosis claim 1 , scleroderma claim 1 , granulomatous vasculitis claim 1 , Crohn's disease claim 1 , ulcerative colitis claim 1 , Sjogren's disease claim 1 , ankylosing spondylitis claim 1 , polymyositis dermatomyositis claim 1 , polyarteritis nodosa claim 1 , immunologically mediated blistering skin diseases claim 1 , Behcet's syndrome claim 1 , multiple sclerosis claim 1 , systemic sclerosis claim 1 , Goodpasture's disease or immune mediated glomerulonephritis.5. The method of claim 1 , wherein neuropeptide Y is administered in a dose from about 1.0 mg to about 50 mg.6. The method of claim 5 , wherein tocilizumab is administered in a dose from about 10 mg.7. The method of claim 1 , wherein said tocilizumab administration decreases levels of IL-6 claim 1 , Th1-like cytokines IL-2 claim 1 , IL-12 claim 1 , TNF-a and IFN-g.8. The method of claim 1 , wherein said tocilizumab administration increases levels of IL-4 claim 1 , IL-10 and IL-13.9. The method of claim 1 , further comprising administering a compound selected from the group consisting of a SIRS peptide claim 1 , a-MSH claim 1 , ACTH and SST.10. A method of decreasing innate inflammatory cytokines IL-1b and TNF-a claim ...

IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS

The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. 1. A method , comprising:administering, to the skin of a subject to modulate the immune system of the subject, a composition comprising an effective amount of gonadotropin-releasing hormone (GnRH) and nitric oxide to modulate the immune system, and a carrier having a phosphatidylcholine component entrapping the nitric oxide.2. The method of claim 1 , wherein the composition further comprises thyrotropin-releasing hormone (TRH).3. The method of claim 1 , wherein the composition further comprises melanocyte-stimulating hormone (MSH).4. The method of claim 1 , wherein the composition further comprises the amino acid sequence KPV.5. The method of claim 3 , wherein the composition further comprises an effective amount of MSH.6. The method of claim 4 , wherein the composition further comprises an effective amount of a peptide comprising the amino acid sequence KPV.7. The method of claim 1 , wherein the nitric oxide is molecular nitric oxide.8. The method of claim 7 , wherein the molecular nitric oxide is present within the carrier as a gas or bound by hydrogen bonds or van der Waals forces. ...

METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. 1. A method , comprising:administering, to the skin of a subject having or at risk of cancer, a composition comprising an effective amount of a peptide and molecular nitric oxide to treat or prevent the cancer, and a carrier having a phosphatidylcholine component entrapping the molecular nitric oxide, wherein the molecular nitric oxide is present within the carrier as a gas or bound by hydrogen bonds or van der Waals forces.2. The method of claim 1 , wherein the peptide comprises thyrotropin-releasing hormone (TRH).3. The method of claim 1 , wherein the peptide comprises melanocyte-stimulating hormone (MSH).4. The method of claim 1 , wherein the phosphatidylcholine carrier stabilizes the nitric oxide at a temperature at or lower than 80° C.57-. (canceled)8. The method of claim 1 , wherein the composition comprises a liquid crystal structure comprising the phosphatidylcholine.9. The method of claim 8 , wherein at least a portion of the liquid crystal structure is multilamellar.10. A method claim 8 , comprising contacting the skin of a subject having or at risk of cancer with a composition comprising:an emulsion comprising a first phase comprising a peptide, molecular nitric ...

USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSION

The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension. 1. A method for treating female sexual dysfunction in a female patient diagnosed with both female sexual dysfunction and controlled hypertension , said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient , when the patient is anticipating sexual activity , wherein the composition comprises 1.00 mg to 1.75 mg net peptide weight of bremelanotide , and wherein only one injection is administered within 24 hours , and no more than eight injections are administered in a month , thereby treating female sexual dysfunction.2. A method for treating female sexual dysfunction in a female patient diagnosed with both female sexual dysfunction and controlled hypertension , said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient , when the patient is anticipating sexual activity , the composition comprising an amount of bremelanotide sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/mL within 60 minutes after administration of the composition , and wherein only one injection is administered within 24 hours , and no more than eight injections are administered in a month , thereby treating female sexual dysfunction.3. A method for treating female sexual dysfunction in a female patient diagnosed with both female sexual dysfunction and controlled hypertension , said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient , when the patient is anticipating sexual ...

COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO

Compositions and methods are disclosed for treating hypomelanotic conditions such as vitiligo and promoting melanogenesis. 1. A composition comprising: a) a cosmeceutically acceptable vehicle , b) rapamycin , c) a growth factor comprising fibroblast growth factor , stem cell factor or endothelins; and d) a cAMP activator.2. A composition according to claim 1 , wherein the composition comprises about 2 weight percent or less rapamycin.3. A composition according to claim 1 , wherein the composition comprises about 0.1 weight percent or less growth factor.4. The composition according to claim 1 , wherein the cAMP activator comprises forskolin or colforsin.5. A composition according to claim 1 , wherein the composition comprises about 2 weight percent or less cAMP activator.6. The composition according to claim 1 , further comprising a melanogenesis activator.7. The composition according to claim 6 , wherein the melanogenesis activator comprises: alpha melanocyte stimulating hormone claim 6 , l-DOPA claim 6 , L-Tyrosine (or N-acetyl L-Tyrosine) claim 6 , or L-phenylalanine.8. The composition according to claim 6 , wherein the composition comprises about 5 weight percent or less melanogenesis activator.9. The composition according to claim 1 , further comprising a melanogenesis substrate.10. The composition according to claim 9 , wherein the melanogenesis substrate comprises l-DOPA claim 9 , L-Tyrosine (or N-acetyl L-Tyrosine) claim 9 , or L-phenylalanine.11. The composition according to claim 9 , wherein the composition comprises about 5 weight percent or less melanogenesis substrate.12. The composition according to claim 1 , further comprising an antioxidant.13. The composition according to claim 12 , wherein the antioxidant comprises vitamin E or catalase.14. The composition according to claim 12 , wherein the composition comprises about 10 weight percent or less antioxidant.15. The composition according to claim 1 , wherein the composition promotes the proliferation ...

USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION

Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects. 125-. (canceled)26. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction and anticipating sexual activity , said method comprising administering to the female patient by subcutaneous injection a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide in an amount sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/mL within 60 minutes after administration of the composition.27. The method of claim 26 , wherein the peak plasma concentration of bremelanotide is no more than 100 ng/mL within 60 minutes after administration of the composition.28. The method of claim 26 , wherein the composition comprises 1.75 mg net peptide weight of bremelanotide.29. The method of claim 26 , wherein the composition is an aqueous solution comprising an acetate salt of bremelanotide and glycerin.30. The method of claim 29 , wherein the composition comprises 2.5% glycerin (w/v).31. The method of claim 29 , wherein the acetate salt of bremelanotide is between 6% and 12% acetic acid (w/w) in an aqueous solution of bremelanotide.32. The method of claim 31 , wherein the composition has a pH of about 5.0 claim 31 , and wherein the composition further comprises one or more agents to adjust pH.33. The method of claim 32 , wherein the one or more agents to adjust pH are selected from the group consisting of hydrochloric acid and sodium hydroxide.34. The method of claim 33 , wherein the composition comprises 1.75 mg net peptide weight of bremelanotide.35. The method of claim 26 , wherein the female patient is premenopausal.36. The method of claim 26 , wherein the female patient is postmenopausal.37. The method ...

METHODS OF INDUCING MELANOGENESIS IN A SUBJECT

Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors. 1. A method for inducing melanogenesis in a human subject comprising administering to the subject an alpha-MSH analogue in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of the subject , wherein the alpha-MSH analogue is [Nle , D-Phe]-alpha-MSH , wherein the alpha-MSH analogue is administered in a delivery system that releases the alpha-MSH analogue in the subject for at least 2 days , and wherein the alpha-MSH analogue is administered at a level not exceeding 10 ng/ml in the plasma of the subject for a period of at least 24 hours.2. A method for reducing the occurrence of UV radiation-induced skin damage in a human subject comprising administering to the subject an alpha-MSH analogue in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of the subject , wherein the alpha-MSH analogue is [Nle , D-Phe]-alpha-MSH , wherein the alpha-MSH analogue is administered in a delivery system that releases the alpha-MSH analogue in the subject for at least 2 days , and wherein the alpha-MSH analogue is administered at a level not exceeding 10 ng/ml in the plasma of the subject for a period of at least 24 hours.3. The method of claim 1 , wherein the delivery system comprises up to 20 mg of alpha-MSH analogue.4. The method of claim 1 , wherein the delivery system comprises from 5 mg of alpha-MSH analogue.5. The method of claim 1 , wherein the delivery system comprises from 10 mg to 20 mg of alpha-MSH analogue.6. The method of claim 1 , wherein the alpha-MSH analogue is released for at least 4 days.7. The method of claim 1 , wherein the alpha-MSH analogue ...

PHARMACEUTICAL COMPOSITIONS AND METHODS

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. 1. A method of treating prostate cancer in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor; a melanin promoter; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor to the subject in need thereof , wherein:the melanin promoter is methoxsalen or melanotan II;the p450 3A4 promoter is 5,5-diphenylhydantoin, valproic acid, or carbamazepine; andthe leucine aminopeptidase inhibitor is N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine or rapamycin.2. The method of further comprising administering a growth hormone inhibitor.3. The method of wherein at least two of the promoters and inhibitors are administered simultaneously.4. The method of wherein at least three of the promoters and inhibitors are administered simultaneously.5. The method of wherein each of the promoters and inhibitors is administered simultaneously.6. The method of wherein the promoters and inhibitors are administered orally claim 1 , subcutaneously claim 1 , intravenously claim 1 , transdermally claim 1 , vaginally claim 1 , rectally or in any combination thereof.7. The method of wherein the transdermal administration is done with oleic acid claim 6 , 1-methyl-2-pyrrolidone claim 6 , or dodecylnonaoxyethylene glycol monoether.8. The ...

PHARMACEUTICAL COMPOSITIONS AND METHODS

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. 1. A method of treating pancreatic cancer in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor; a melanin promoter; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor to the subject in need thereof , wherein:the melanin promoter is methoxsalen or melanotan II;the p450 3A4 promoter is 5,5-diphenylhydantoin, valproic acid, or carbamazepine; andthe leucine aminopeptidase inhibitor is N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine or rapamycin.2. The method of further comprising administering a growth hormone inhibitor.3. The method of wherein at least two of the promoters and inhibitors are administered simultaneously.4. The method of wherein at least three of the promoters and inhibitors are administered simultaneously.5. The method of wherein each of the promoters and inhibitors is administered simultaneously.6. The method of wherein the promoters and inhibitors are administered orally claim 1 , subcutaneously claim 1 , intravenously claim 1 , transdermally claim 1 , vaginally claim 1 , rectally or in any combination thereof.7. The method of wherein the transdermal administration is done with oleic acid claim 6 , 1-methyl-2-pyrrolidone claim 6 , or dodecylnonaoxyethylene glycol monoether.8. The ...

Pharmaceutical Compositions And Methods

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. 1. A method of treating pancreatic cancer in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor; a melanin promoter; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor to the subject in need thereof , wherein:the melanin promoter is methoxsalen or melanotan II;the p450 3A4 promoter is 5, 5-diphenylhydantoin, valproic acid, or carbamazepine; andthe leucine aminopeptidase inhibitor is N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine or rapamycin.2. The method of further comprising administering a growth hormone inhibitor.3. The method of wherein at least two of the promoters and inhibitors are administered simultaneously.4. The method of wherein at least three of the promoters and inhibitors are administered simultaneously.5. The method of wherein each of the promoters and inhibitors is administered simultaneously.6. The method of wherein the promoters and inhibitors are administered orally claim 1 , subcutaneously claim 1 , intravenously claim 1 , transdermally claim 1 , vaginally claim 1 , rectally or in any combination thereof.7. The method of wherein the transdermal administration is done with oleic acid claim 6 , 1-methyl-2-pyrrolidone claim 6 , or dodecylnonaoxyethylene glycol monoether.8. The ...

Pharmaceutical Compositions And Methods

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof 131-. (canceled)32. A method of making cancer cells more accessible to oxidative stress , comprising contacting said cancer cells with an effective amount of a tyrosine hydroxylase inhibitor.33. The method of claim 32 , wherein said tyrosine hydroxylase inhibitor accumulates in said cancer cells.34. The method of claim 32 , wherein said tyrosine hydroxylase inhibitor prevents formation of a coating of lipids in said cancer cells.35. The method of claim 32 , wherein said tyrosine hydroxylase inhibitor prevents formation of a coating of hyaluron in said cancer cells.36. The method of claim 32 , wherein said contacting is effected by administering said effective amount of said tyrosine hydroxylase inhibitor to a subject in whom said cancer cells reside.37. The method of claim 32 , wherein said tyrosine hydroxylase inhibitor is administered orally claim 32 , subcutaneously claim 32 , intravenously claim 32 , transdermally claim 32 , vaginally claim 32 , or rectally.38. The method of claim 32 , wherein said tyrosine hydroxylase inhibitor is a tyrosine derivative.39. The method of claim 38 , wherein the tyrosine derivative is one or more of methyl (2R)-2-amino-3-(2-chloro-4 hydroxyphenyl) propanoate claim 38 , D-tyrosine ethyl ester hydrochloride claim 38 , ...

COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS

A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo. 1. A combination product comprising at least one prostaglandin receptor agonist and at least one MC1R receptor agonist , as a medicament for use simultaneously , separately or spread out over time for the treatment of dermatological conditions linked to hypopigmentation.2. The product as claimed in claim 1 , wherein the dermatological conditions are selected from the group consisting of vitiligo claim 1 , albinism claim 1 , hypomelanosis claim 1 , depigmentations caused by physical or chemical agents claim 1 , post-inflammatory hypopigmentations claim 1 , Sutton's phenomenon and other hypopigmentary lesions.3. The product as claimed in claim 2 , wherein the dermatological condition is vitiligo.4. The product as claimed in claim 1 , wherein the prostaglandin receptor agonist and the MC1R receptor agonist are present in the same composition.51. The product as claimed in claim in claim 1 , wherein the prostaglandin receptor agonist and the MC1R receptor agonist are present separately from one another in distinct compositions.6. The product as claimed in claim 5 , wherein the composition comprising the prostaglandin receptor agonist is administered first claim 5 , and then the composition comprising the MC1R receptor agonist is administered second.7. The product as claimed in claim 4 , wherein the prostaglandin receptor agonist is present at a concentration of between approximately 0.001% and 1% by weight claim 4 , relative to the total weight of the composition comprising it.8. The product as claimed in claim 4 , wherein the MC1R receptor ...

SYSTEMS AND METHODS FOR DELIVERY OF PEPTIDES

The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. 163-. (canceled)64. A composition , comprising:a carrier comprising thyrotropin-releasing hormone (TRH) and lecithin entrapping molecular nitric oxide, wherein the composition is stable at room temperature.65. The composition of claim 64 , wherein the carrier further comprises polyenylphosphatidylcholine.66. The composition of claim 64 , wherein the composition comprises a liquid crystal structure.67. The composition of claim 64 , wherein the composition comprises no more than about 250 ppm of water by weight of the composition.68. The composition of claim 64 , wherein the lecithin is present at at least about 0.25% by weight of the composition.69. The composition of claim 64 , wherein the molecular nitric oxide is present at at least about 0.5% by weight of the composition without nitric oxide.70. The composition of claim 64 , wherein the molecular nitric oxide is present within the composition as a gas.71. The composition of claim 64 , wherein the molecular nitric oxide is bound by hydrogen bonds or van der Waals forces to the lecithin.72. The composition of ...

Memory or learning improvement using peptide and other compositions

The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Pharmaceutical Compositions And Methods

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. 1. A method of treating pancreatic cancer in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor; a melanin promoter; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor to the subject in need thereof , wherein:the melanin promoter is methoxsalen or melanotan II;the p450 3A4 promoter is 5, 5-diphenylhydantoin, valproic acid, or carbamazepine; andthe leucine aminopeptidase inhibitor is N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine or rapamycin.2. The method of further comprising administering a growth hormone inhibitor.3. The method of wherein at least two of the promoters and inhibitors are administered simultaneously.4. The method of wherein at least three of the promoters and inhibitors are administered simultaneously.5. The method of wherein each of the promoters and inhibitors is administered simultaneously.6. The method of wherein the promoters and inhibitors are administered orally claim 1 , subcutaneously claim 1 , intravenously claim 1 , transdermally claim 1 , vaginally claim 1 , rectally or in any combination thereof.7. The method of wherein the transdermal administration is done with oleic acid claim 6 , 1-methyl-2-pyrrolidone claim 6 , or dodecylnonaoxyethylene glycol monoether.8. The ...

NEW INDICATION FOR ALPHA-MSH ANALOGUES

The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders. 1. Alpha-MSH analogue for use in treatment of a human subject with a neurodegenerative disorder wherein the interval between subsequent administrations of the alpha-MSH analogue is between at least 6 weeks and at most 8 weeks.2. Compound for use according to claim 1 , wherein the disorder is a juvenile form of the neurodegenerative disorder.3. Compound for use according to claim 1 , wherein the neurodegenerative disorder is Multiple Sclerosis.4. Compound for use according to claim 1 , wherein the neurodegenerative disorder is dementia.5. Compound for use according to claim 1 , wherein the neurodegenerative disorder is Alzheimer's Disease.6. Compound for use according to claim 1 , wherein the neurodegenerative disorder is Parkinson's Disease.7. Compound for use according to claim 1 , wherein the neurodegenerative disorder is Amyotrophic Lateral Sclerosis (ALS).8. Compound for use according to claim 1 , wherein the neurodegenerative disorder is Huntington's Disease.9. Compound for use according to claim 1 , wherein the alpha-MSH analogue is administered systemically.10. Compound for use according to claim 1 , wherein the alpha-MSH analogue is administered subcutaneously.11. Compound for use according to claim 1 , the alpha-MSH analogue is present in the blood plasma of the subject at a level of between at least 0.01 ng/ml to at most 10 ng/ml for a period of at least 2 days after administration.12. Compound for use according to claim 1 , wherein the alpha-MSH analogue is a derivative of alpha-MSH which exhibits agonist activity for the melanocortin-1-receptor (MC1R) claim 1 , the receptor to which alpha-MSH binds to initiate the production of melanin within a melanocyte.13. Compound for use according to claim 1 , wherein the alpha-MSH analogue is afamelanotide.14. Method of treating neurodegenerative disorders by administering an alpha-MSH analogue to a human subject ...

TOPICAL SYSTEMS AND METHODS FOR TREATING SEXUAL DYSFUNCTION

The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. 158-. (canceled)59. A method , comprising:administering, to a subject having or at risk of sexual dysfunction, a composition comprising an effective amount of molecular nitric oxide and a peptide to treat or prevent the sexual dysfunction, and a carrier comprising phosphatidylcholine containing the molecular nitric oxide, wherein the composition is stable at room temperature.60. The method of claim 59 , wherein the composition is administered to a mucosal surface of the subject.61. The method of claim 59 , wherein the subject is female claim 59 , and the composition is administered to the vulva of the female subject.62. The method of claim 59 , wherein the subject is male claim 59 , and the composition is administered to the penis of the male subject.63. The method of claim 59 , wherein the composition comprises polyenylphosphatidylcholine.64. The method of claim 59 , wherein the composition ...

Topical systems and methods for treating sexual dysfunction

The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Brain and neural treatments comprising peptides and other compositions

The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

INFLAMMATORY DISEASE

The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease. 1. Alpha-MSH analogue for use in treatment of a human subject with inflammatory disease wherein the interval between subsequent administrations of the alpha-MSH analogue is between at least 5 weeks and at most 8 weeks.2. Compound for use according to claim 1 , wherein the inflammatory disease is inflammatory bowel disease (IBD).3. Compound for use according to claim 1 , wherein the inflammatory disease is uveitis.4. Compound for use according to claim 1 , wherein the inflammatory disease is nephritis.5. Compound for use according to claim 1 , wherein the inflammatory disease is rheumatoid arthritis.6. Compound for use according to claim 1 , wherein the alpha-MSH analogue is administered systemically.7. Compound for use according to claim 1 , wherein the alpha-MSH analogue is administered subcutaneously.8. Compound for use according to claim 1 , wherein the alpha-MSH analogue is present in the blood plasma of the subject at a level of between at least 0.01 ng/ml to at most 10 ng/ml for a period of at least 2 days after administration.9. Compound for use according to claim 1 , wherein the alpha-MSH analogue is administered at least 3 times to the subject.10. Compound for use according to claim 1 , wherein the alpha-MSH analogue is a derivative of alpha-MSH which exhibits agonist activity for the melanocortin-l-receptor (MC1R) claim 1 , the receptor to which alpha-MSH binds to initiate the production of melanin within a melanocyte.11. Compound for use according to claim 1 , wherein the alpha-MSH analogue is afamelanotide.12. Method of treating inflammatory disease by administering an alpha-MSH analogue to a human subject suffering from inflammatory disease claim 1 , wherein the interval between subsequent administrations of the alpha-MSH analogue is at least 5 weeks and at most 8 weeks.13. Use of an alpha-MSH analogue for the manufacture of a medicament for the treatment of ...

Compound and method for the treatment of sinusitis

The invention includes a composition and method of treatment of sinusitis. A preferred embodiment of the invention is a composition for treatment of sinusitis comprising a therapeutically effective amount of one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV used in combination with a therapeutically effective amount of an antihistamine/decongestant, corticosteroid, fungicide and/or antibiotic. In yet another embodiment of the invention, one or one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV, which may or may not be in combination with therapeutically effective amounts of antibiotics, corticosteroids and/or antihistamine/decongestants, are topically or systemically applied to treat sinusitis.

USE OF LYS-PRO-VAL TRIPEPTIDE (KPV) TO PROMOTE EPIDERMIC RENEWAL AND SUPERFICIAL CUTANEOUS MICRO-HEALING AND / OR IMPROVE AESTHETIC APPEARANCE OF WOUNDS AND SCARS

Drug for promotion or stimulation of hair growth

Drug for the promotion or stimulation of hair growth and/or the prevention of hair loss contains at least one peptide contg. a tripeptide of Lys-Pro-Val (LPV) or its functional equivalent except those in which the histidine residue is present just upstream of the LPV sequence. Also claimed are a drug for the treatment of the inflammatory stage of depilation contg. the above peptide, and a method for treating hair and/or the scalp in which a compsn. of the above drug is applied on the hair and/or the scalp and stood and then rinsed.

Agent for promoting or stimulating hair growth and / or preventing hair loss

Composition and method for regulation of body weight and associated conditions

Described are methods and compositions for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of circulating proopiomelanocortin peptides or analogs thereof to an animal, alone or in combination with leptin or other body weight regulating agents are disclosed. Methods and compositions for treating a variety of disorders associated with or caused by undesirable body weight are also described.

Implantable pump for protein delivery for obesity control by drug infusion into the brain

Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor on a neural cell in the central nervous system and modifies the receptor function to suppress appetite.

Method of stimulation of melanin production and induction of skin tanning

Compounds capable of binding to melanocortin 4 receptor

The present invention relates to novel peptide compounds which are effective as melanocortin 4 receptor agonists, to the use of the compounds in medicine, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds for the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of overweight and obesity as well as a variety of diseases or conditions associated with obesity.

Human anti-inflammatory peptides for the inhalatory treatment of inflammatory pulmonary diseases

The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

Treatment of synucleinopathy and animal models of synucleinopathy

Treatments for synucleinopathy including Parkinson's Disease (PD), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB) are largely unavailable. The invention provides methods for treating, preventing, inhibiting, and reversing synucleinopathy by attenuating MSH activity, decreasing MSH expression, or by modulating MSH engagement with its receptor by utilizing antagonists. Furthermore, the inventor has provided a method for producing a synucleinopathy animal model for screening treatments and for studying synuclein disease pathology.

Enhanced melanoma cancer prevention by novel melanotropins

A gamma-melanocyte stimulating hormone (γ-MSH) derivative having improved stability, selectivity and bioavailabilty. The γ-MSH derivative is selective for the melanocortin-1 receptor (MC1 R) and is deliverable to skin cells via topical or transdermal delivery. The γ-MSH derivative is made up of naturally occurring amino acids for stimulating melanin from within for photoprotection of human skin against ultraviolet radiation damage.

Use of KPV tripeptide for dermatological disorders

The present invention is directed to a prevention and treatment for dermatological disorders. One aspect of this invention involves a dermatological treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV (SEQ. ID. NO. 4) for the treatment and prevention of dermatological disorders. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above.

Human Anti-inflammatory Peptides for Inhaled Treatment of Inflammatory Pulmonary Disease

본 발명은 염증성 폐 질환의 흡입식 치료에의 인간 항염증성 펩타이드의 용도에 관한 것이다. 본 발명은 특히 상기 목적을 위한 혈관작용 장 펩타이드, C형 나트륨이뇨 펩타이드, B형 나트륨이뇨 펩타이드, 뇌하수체 아데닐산 고리화효소 활성화 펩타이드, 아드레노메둘린, 알파-멜라닌 세포 자극 호르몬, 릴랙신, 및 인터페론 감마의 용도에 관한 것이다. 이러한 인간 항염증성 펩타이드를 함유하는 에어로졸의 이로운 특성 및 상기 에어로졸의 제조 방법이 개시된다. 본 발명은 추가로 염증성 폐 질환의 흡입식 치료를 위한 키트에 관한 것이다. 일 양태는 CoViD-19 관련 ARDS의 치료에 관한 것이다.

USE OF DERIVATIVES OF THE STIMULATING HORMONE OF MELANOCYTES OF THE ALPHA TYPE TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THEIR FALLING

Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone

The presence of the ancient anti-inflammatory peptide α-melanocyte stimulating hormone (α-MSH [1-13], SYSMEHFRWGKPV) in barrier organs such as gut and skin suggests a role in the nonspecific (innate) host defense system. α-MSH and other amino acid sequences derived from α-MSH were determined to have antimicrobial influences, including against two major and representative cutaneous and mucosal pathogens: Staphylococcus aureus and Candida albicans . α-MSH peptides had antimicrobial effects against S. aureus and significantly reversed the enhancing effect of urokinase on S. aureus colony formation. α-MSH and other amino acid sequences reduced C. albicans viability and germination. α-MSH peptides also enhanced C. albicans killing by human neutrophils. The antimicrobial agent is selected from the group consisting of one or more peptides including the amino acid sequence KPV, one or more peptides including the amino acid sequence MEHFRWG, or a biologically functional equivalent of any of the foregoing. The most effective of the peptides were those bearing the C-terminal amino acid sequence of α-MSH, i.e., α-MSH (1-13), (6-13), and (11-13). The α-MSH “core” sequence (4-10), important for melanotropic effects, was also effective but significantly less potent. Antimicrobial influences of α-MSH peptides could be mediated by their well-known capacity to increase cellular cAMP; this messenger was significantly augmented in peptide-treated yeast. α-MSH has potent anti-inflammatory effects and is expected to be useful for treatment of inflammation in human and veterinary disorders. Reduced killing of pathogens is a detrimental consequence of therapy with corticosteroids and nonsteroidal anti-inflammatory drugs during infection. Therefore, anti-inflammatory agents based on α-MSH peptides that do not reduce microbial killing, but rather enhance it, would be very useful. The antimicrobial effects of these α-MSH peptides occurred over a broad range of concentrations including the ...

Alpha-melanocyte stimulating hormone peptides protection in organ transplantation

A composition and method for controlling host response to organ and/or tissue transplantation and grafting. Alpha-Melanocyte Stimulating Hormone protects organ and tissue transplantation by controlling factors within the donor, host and of the organ or tissue to be transplanted. Treatment with α-MSH and/or its derivatives can affect warm and cold ischemia times and thus promotes organ viability. Treatment of the donor, host and of the organ or tissue to be transplanted with an appropriate dosage of α-MSH and/or its derivatives limits biochemical pathways that would normally work to reject an organ and/or tissue transplantation. α-MSH augments successful graft transplantation whether it be allograft or xenograft.

Alpha-msh analogues for use in the treatment of psoriasis

The present invention relates to alpha-MSH analogues, particularly afamelanotide, for use in treatment of psoriasis as well as to combination treatments.

System and method for support legacy operating system booting in a legacy-free system

The invention includes a composition and method of treatment of sinusitis. A preferred embodiment of the invention is a composition for treatment of sinusitis comprising a therapeutically effective amount of one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV (SEQ ID NO:1), HFRWGKPV (SEQ ID NO:2), and SYSMEHFRWGKPV (SEQ ID NO:3) used in combination with a therapeutically effective amount of an antihistamine/decongestant, corticosteroid, fungicide and/or antibiotic. In yet another embodiment of the invention, one or one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV (SEQ ID NO:1), HFRWGKPV (SEQ ID NO:2), and SYSMEHFRWGKPV (SEQ ID NO:3), which may or may not be in combination with therapeutically effective amounts of antibiotics, corticosteroids and/or antihistamine/decongestants, are topically or systemically applied to treat sinusitis.

Methods of delivering therapeutics to the brain

Intranasal iontophoretic administration of therapeutics such as Reduced Water (RW) or lubeluzole as a means of treating diseases of the CNS involving oxidative stress.

Control of chronic neuropathic pain and allodynia

In one embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia by administering a therapeutically-effective amount of at least one LFA1 antagonist to the subject. In a preferred embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia, the method comprising administering intrathecally to the subject a therapeutically-effective amount of microparticles comprising PLGA-encapsulated pDNA-IL-10, optionally in combination with a therapeutically-effective amount of intrathecally-administered CpG oligodeoxynucleotide (CpG ODN) and/or at least one LFA1 antagonist.

Cancer treatment system

An invention is disclosed for combating cancer. In vitro studies have shown that α-MSH inhibits the proliferation of various mesothelioma cell lines. The invention is directed to a system and method for combating cancer and, in a specific embodiment, mesothelioma. Use of a therapeutic composition containing α-MSH and/or derivatives of α-MSH is disclosed for treatments including but not limited to parenteral administrations, direct targeting of cancer cells, gene therapy and local administrations using a cannula. Certain derivatives of α-MSH, NDP-α-MSH for example, are particularly effective in combating growth in mesothelioma cell lines.

Melanocyte-stimulation hormone for suppressing inflammation reactions in hemodialysis

Human anti-inflammatory peptides for the inhalatory treatment of inflammatory pulmonary diseases

Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome

Use of ocular neuropeptides as immune adjuvants

The present invention is directed to methods and compositions relating to immune adjuvants. The present invention is also related to ocular neuropeptides used in compositions and methods of modulating immune responses.

Method of stimulation of melanin production and induction of skin tanning

A method of stimulating the production of melanin by the pigment-producing cells (keratinocytes and/or melanocytes) of the skin, in particular for the induction of skin tanning in humans, comprises administering alpha-MSH or an alpha-MSH analogue and exposing the skin to ultraviolet irradiation.

Brain and neural treatments comprising peptides and other compositions

The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorders, including brain disorders. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptides may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth, muscle repair, or improved muscular and neuromuscular control is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Composition and method for regulation of body weight and associated conditions

Methods for regulating body weight and/or regulating weight gain are provided herein. The methods are useful, for instance, for treating or preventing obesity. Specifically, methods of administering varying levels of various alpha melanocyte stimulating hormone (α-MSH) analog compounds to an animal are provided for reducing body weight and/or reducing the rate of body weight gain.

Inflammatory disease

The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease.

Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome

The present invention discloses methods of treating or inhibiting one or more of sick building syndrome (SBS), post-Lyme Disease Syndrome (PLDS), and chronic fatigue syndrome (CFS) by administering to a patient in need thereof an amount effective of cholestyramine and/or α-melanocyte stimulating hormone to treat or inhibit one or more of these syndromes.

Use of bremelanotide in patients with controlled hypertension

The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.

Novel modulators of melanocortin receptors

A backbone N-methylation approach on SHU9119, a non-selective cyclic peptide antagonist at hMC3R and hMC4R. Systematic N-methylated derivatives of SHU9119, with all possible backbone N-methylation combinations have been synthesized and examined for their binding and functional activities towards melanocortin receptor subtypes 1, 3, 4 and 5 (hMCRs). Several N-methylated analogues, which have selective and potent agonists or antagonists activity for the hMC1R or hMC5R or selective antagonist activity for the hMC3R, are discovered from the library. The selective hMC1R ligands show strong binding for human melanoma cells. The first universal antagonist for all subtypes of hMCRs will be of critical importance to modulate the melanocortin system with endogenous agonists.

Compound comprising alpha-msh for use in endodontic regeneration

The present invention concerns a compound comprising an α-MSH peptide, coupled to a polypeptide consisting of a chain of about 15 to about 400 amino acids, for use in endodontic regeneration and/or for the treatment of dental inflammatory diseases. The invention further concerns pharmaceutical compositions, in particular nanostructured compositions, comprising such a compound.

Peptidos antiinflamatorios humanos para el tratamiento inhalatorio de enfermedades pulmonares inflamatorias.

La presente invención se relaciona con el uso de péptidos antiinflamatorios humanos en el tratamiento por inhalación de enfermedades pulmonares inflamatorias. La invención en particular se relaciona con el uso de péptido intestinal vasoactivo, péptido natriurético tipo C, péptido natriurético tipo B, péptido activador de adenilatociclasa pituitaria, adrenomedulina, hormona estimuladora de a-melanocito, relaxina e interferón gamma para dichos fines. Se describen características ventajosas de un aerosol que contiene tal péptido antiinflamatorio humano y un método para producir dicho aerosol. La presente invención se relaciona además con un kit para el tratamiento inhalatorio de enfermedades pulmonares inflamatorias. Un aspecto se relaciona con el tratamiento de ARDS relacionados con el CoViD-19.

Treatment of ophthalmic infections using antimicrobial peptides

The present invention discloses a use by administering to a vertebrate inflicted with the ophthalmic infection a therapeutically effective amount of an antimicrobial peptide which is derived from alpha-melanocyte-stimulating hormone (a-MSH) and biologically functional equivalents thereof. Specifically, the antimicrobial peptides derived from alpha-melanocyte-stimulating hormone (a-MSH) include a-MSH (1-13) which is SYSMEHFRWGKPV (SEQ ID NO: 4), a-MSH (4-10) which is MEHFRWG (SEQ ID NO: 2), a-MSH (6-13) which is HFRWGKPV (SEQ ID NO: 3), a-MSH (11-13) which is KPV (SEQ ID NO: 1), and a KPV dimer (SEQ ID NO: 5). The ophthalmic infection can be caused by a microorganism which include a bacteria, a fungi or a virus. The vertebrate includes a bird and a mammal. The antimicrobial peptide has anti-bacterial, antifungal, and antiviral properties and therefore can be administered at the onset of the ophthalmic infection before the microorganism causing the infection is determined as well as thereafter.

Treatment of hiv

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.

Ｈｉｖ 치료

본 발명은 프로오피오멜라노코르틴(proopiomelanocortin: POMC) 및 부신 피질 자극 호르몬 방출 인자(corticotropin releasing factor: CRF) 펩티드를 이용한 HIV 치료 방법 및 의약제 제조에 상기 펩티드를 이용하는 용도뿐만 아니라 이의 산물에 관한 것이다.

Methods and compositions for treating premature rupture of fetal membranes

Methods and pharmaceutical compositions useful in the treatment and prevention of preterm premature rupture of the fetal membranes (PROM) in pregnant human patients are provided.

Treatment of HIV

Treatment of hiv

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.

Treatment of hiv

Treatment of HIV comprising administering a corticotropin releasing factor (CRF) peptide

Disclosed is the use of a corticotropin releasing factor (CRF) peptide and a POMC peptide or POMC product in the manufacture of a medicament for the treatment of HIV.

Tratamiento contra el vih.

Describimos métodos para el tratamiento del VIH usando péptidos proopiomelanocortina (POMC) y factor de liberación de corticotropina (CRF) y sus productos, así como también usos de estos péptidos en la preparación de medicamentos.

Corticotropin releasing factor (crf) and proopiomelanocortin (pomc) for use in treatment of hiv

Treatment of hiv using proopiomelanocortin (pomc) and corticotropin releasing factor (crf) and their products

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.

Ｈｉｖの治療

Treatment of hiv

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.

Treatment of hiv

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.

Methods and compositions for treating premature rupture of fetal membranes

Methods and compositions for treating premature rupture of fetal membranes

Methods and pharmaceutical compositions useful in the treatment and prevention of preterm premature rupture of the fetal membranes (PROM) in pregnant human patients are provided.

New methods of use of acth analogs

The present invention provides a method for preventing brain injury related to cognitive deficits, long term cerebrovascular histopathological effects of organophosphates, cochlear injury, all related to reducing the permeability of microvasculature, maintaining vascular impermeability and preventing blood cell adhesion to the vasculature in injured neuronal sites by the administration of an analog of amino acids 1-14 of adrenocorticotropin hormone.

Metallopeptide compounds

Metallopeptides with a sequence of a biologically active alpha-melanocyte stimulating hormone (α-MSH), gamma-melanocyte stimulating hormone (γ-MSH), or bombesin sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side of the n position, or alternatively is substituted for the residue at any position from the three position to the n position, with a metal ion complexed thereto, with any proline (Pro) residue which is either of the two residues on the immediately adjacent N-terminus side of the inserted or substituent residue comprising a nitrogen atom and sulfur atom available for complexation to a metal ion is substituted with a homolog.

用于吸入治疗炎症性肺病的人抗炎肽

本发明涉及人抗炎肽在炎症性肺病的吸入治疗中的用途。本发明特别涉及血管活性肠肽、C型利钠肽、B型利钠肽、垂体腺苷酸环化酶激活肽、肾上腺髓质素、α‑黑素细胞刺激激素、松弛素和干扰素γ的用于所述目的的用途。公开了含有此类人抗炎肽的气溶胶的有利特征和用于制备所述气溶胶的方法。本发明还涉及用于吸入治疗炎症性肺病的试剂盒。一个方面涉及CoViD‑19相关ARDS的治疗。

Topical systems and methods for treating sexual dysfunction

The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Memory or learning improvement using peptide and other compositions

The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.